Revelation Biosciences, Inc.
REVB
$0.91
-$0.04-3.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 47.61% | 46.78% | -60.79% | -12,400.83% | -1,873.22% |
| Total Depreciation and Amortization | 5.19% | 10.34% | 14.29% | 10.71% | 7.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,654.69% | 506.11% | 176.02% | 101.38% | 100.08% |
| Change in Net Operating Assets | -106.07% | -238.86% | -584.04% | -448.56% | -212.37% |
| Cash from Operations | 39.37% | -96.08% | -113.80% | -151.45% | -166.03% |
| Capital Expenditure | 147.97% | 100.00% | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 147.97% | 100.00% | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 76.86% | 99.72% | 37.17% | -8.43% | -34.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 100.00% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 76.86% | 99.72% | 37.17% | -8.39% | -34.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.75% | -89.63% | -244.23% | -181.51% | -195.57% |